title: Prolonged renal parenchymal retention of 99mTc mercaptoacetyltriglycine after nephron-sparing surgery.
abstract: OBJECTIVE
  Nephron-sparing surgery is a treatment in which a part of a diseased kidney is resected and some parenchyma of the kidney is spared. Impairment of spared renal parenchyma after the surgery may cause prolonged prarenchymal retention in renal scintigraphy with Tc mercaptoacetyltriglycine (Tc-MAG3). The aim of this study was to determine whether or not parenchymal retention of Tc-MAG3 is prolonged after nephron-sparing surgery.
  
  
  METHODS
  Twenty-two patients underwent a total of 29 Tc-MAG3 studies within 1 year after nephron-sparing surgery. In 17 patients (23 examinations) who had bilateral kidneys, the presence of diffuse prolongation of parenchymal retention was determined for the operated kidney. In all patients, the presence of regional prolongation around the surgical margin was assessed.
  
  
  RESULTS
  Diffuse prolongation was observed in four of 10 examinations performed within 1 month after surgery and in none of 13 examinations performed later than 1 month after surgery. Regional prolongation was shown in 10 of 14 examinations performed within 1 month after surgery and in three of 15 examinations performed later than 1 month after surgery. In five patients who were studied both prior to and later than 1 month after surgery, regional prolongation was noted on the first study. On the second study, regional prolongation was improved and initial renal uptake around the surgical margin was intensified.
  
  
  CONCLUSIONS
  Renal parenchymal retention of Tc-MAG3 is frequently prolonged in the early period after nephron-sparing surgery. Renal scintigraphy with Tc-MAG3 may aid in characterizing acute renal damage after nephron-sparing surgery.
authors.affiliation: Department of Radiology, Institute of Medical Science, Graduate School of Medicine, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan. inoueys-tky@umin.ac.jp
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Inoue
authors.forename: Shigeharu
authors.initials: S
authors.lastname: Kurimoto
authors.forename: Shuji
authors.initials: S
authors.lastname: Kameyama
authors.forename: Nobutaka
authors.initials: N
authors.lastname: Ohta
authors.forename: Masaaki
authors.initials: M
authors.lastname: Akahane
authors.forename: Kohki
authors.initials: K
authors.lastname: Yoshikawa
authors.forename: Ikuo
authors.initials: I
authors.lastname: Yokoyama
authors.forename: Manabu
authors.initials: M
authors.lastname: Minami
authors.forename: Kuni
authors.initials: K
authors.lastname: Ohtomo
authors.forename: Tadaichi
authors.initials: T
authors.lastname: Kitamura
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D016477:Artifacts; D005260:Female; D006801:Humans; D007668:Kidney / Q000000981:diagnostic imaging / Q000378:metabolism* / Q000601:surgery*; D007680:Kidney Neoplasms / Q000000981:diagnostic imaging / Q000378:metabolism* / Q000601:surgery*; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D019060:Minimally Invasive Surgical Procedures / Q000379:methods; D009392:Nephrectomy / Q000379:methods*; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D017263:Technetium Tc 99m Mertiatide / Q000493:pharmacokinetics*; D013997:Time Factors; D014018:Tissue Distribution
chemical_list: D019275:Radiopharmaceuticals; D017263:Technetium Tc 99m Mertiatide